Cite

HARVARD Citation

    Früh, M. et al. (2019). EGFR mutation subtype impacts efficacy of immune checkpoint inhibitors in non-small-cell lung cancer. Annals of oncology. pp. 1190-1192. [Online]. 
  
Back to record